Beyond Air to Participate in the ROTH 4th Annual Healthcare Opportunities Conference

Rhea-AI Summary

Beyond Air (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company specializing in nitric oxide (NO) treatments, announced its participation in the ROTH 4th Annual Healthcare Opportunities Conference. The event will take place on October 9, 2025, in New York, NY.

The company's Chief Financial Officer, Douglas Larson, will be available for one-on-one meetings with investors during the conference. Interested investors can schedule meetings through their Roth Capital Partners representatives.

GARDEN CITY, N.Y., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Douglas Larson, Chief Financial Officer of Beyond Air, will participate in the ROTH 4th Annual Healthcare Opportunities Conference, which is being held on Thursday, October 9, 2025, in New York, NY.

Mr. Larson will be available for meetings with investors at the conference. If you are interested in requesting a one-on-one meeting, please contact your respective representative at Roth Capital Partners to schedule accordingly.

About Beyond Air^®, Inc.
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit^® PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM).

The Company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.

About LungFit *
Beyond Air's LungFit is a cylinder-free, phasic flow generator and delivery system designated as a medical device by the U.S. Food and Drug Administration (FDA). The ventilator-compatible version of the device can generate NO from ambient air on demand for delivery to the lungs at concentrations ranging from 1 ppm to 80 ppm. The LungFit system could potentially replace large, high-pressure NO cylinders, providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements, improving overall safety by eliminating NO2 purging steps, and offering other operational benefits.

LungFit can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting (e.g., COVID-19, bronchiolitis) and chronic, refractory lung infections in the home setting (e.g., NTM). With the elimination of cylinders, Beyond Air intends to offer NO treatment in the home setting.

*Beyond Air's LungFit PH is approved for commercial use in the United States, European Union, and many other countries around the world. Beyond Air's other LungFit systems are not approved for commercial use and are for investigational use only. Beyond Air is not suggesting NO use over 80 ppm or use at home.

CONTACTS:

Corey Davis, Ph.D.
LifeSci Advisors, LLC
Cdavis@lifesciadvisors.com
(212) 915-2577

FAQ

When is Beyond Air (XAIR) presenting at the ROTH Healthcare Conference 2025?

Beyond Air will participate in the ROTH 4th Annual Healthcare Opportunities Conference on October 9, 2025 in New York, NY.

Who will represent Beyond Air (XAIR) at the ROTH Healthcare Conference?

Douglas Larson, Beyond Air's Chief Financial Officer, will represent the company at the conference.

How can investors schedule meetings with Beyond Air (XAIR) at the ROTH Conference?

Investors can schedule one-on-one meetings with Beyond Air through their Roth Capital Partners representatives.

What is Beyond Air's (XAIR) main business focus?

Beyond Air is a commercial stage medical device and biopharmaceutical company focused on developing nitric oxide (NO) treatments to improve patient lives.